A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 11,610 shares of HALO stock, worth $568,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,610
Previous 11,771 1.37%
Holding current value
$568,890
Previous $616,000 7.79%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$51.3 - $64.42 $8,259 - $10,371
-161 Reduced 1.37%
11,610 $664,000
Q2 2024

Jul 16, 2024

BUY
$37.81 - $52.4 $58,756 - $81,429
1,554 Added 15.21%
11,771 $616,000
Q1 2024

Apr 15, 2024

BUY
$33.68 - $41.95 $344,108 - $428,603
10,217 New
10,217 $415,000
Q3 2023

Nov 13, 2023

BUY
$36.46 - $44.03 $350,234 - $422,952
9,606 New
9,606 $366,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.83B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Wealth Enhancement Advisory Services, LLC Portfolio

Follow Wealth Enhancement Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Enhancement Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Enhancement Advisory Services, LLC with notifications on news.